[{"id":"37515089-1ee4-4286-99b0-7bb0298fc653","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472153","created_at":"2026-03-28T01:41:57.745Z","updated_at":"2026-03-28T01:41:57.745Z","phase":"Phase 2/3","brief_title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","source_id_and_acronym":"NCT07472153","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"ce020719-ee60-4c78-aac1-c9da91de0268","acronym":"GIVEN","url":"https://clinicaltrials.gov/study/NCT07472478","created_at":"2026-03-28T01:39:49.899Z","updated_at":"2026-03-28T01:39:49.899Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","source_id_and_acronym":"NCT07472478 - GIVEN","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-16"},{"id":"f548789f-e984-493e-8c25-7196761bc8df","acronym":"","url":"https://clinicaltrials.gov/study/NCT07153952","created_at":"2025-09-06T13:40:49.515Z","updated_at":"2025-09-06T13:40:49.515Z","phase":"Phase 1/2","brief_title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","source_id_and_acronym":"NCT07153952","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-09-04"},{"id":"c72ecd8f-9c23-45c8-aceb-c2281207ef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT07141771","created_at":"2025-08-30T13:51:58.696Z","updated_at":"2025-08-30T13:51:58.696Z","phase":"Phase 1/2","brief_title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","source_id_and_acronym":"NCT07141771","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • etoposide IV • irinotecan • topotecan • AiRuiYi (fluzoparib) • Zepzelca (lurbinectedin) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-26"},{"id":"bf382896-655a-44da-bab6-a9973e918517","acronym":"","url":"https://clinicaltrials.gov/study/NCT07082179","created_at":"2025-07-26T13:28:21.688Z","updated_at":"2025-07-26T13:28:21.688Z","phase":"Phase 2","brief_title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT07082179","lead_sponsor":"Jiangsu Cancer Institute \u0026 Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-07-24"},{"id":"f5ce8c06-3250-40ff-b25a-dd3430d92b46","acronym":"","url":"https://clinicaltrials.gov/study/NCT07078604","created_at":"2025-07-26T13:31:46.938Z","updated_at":"2025-07-26T13:31:46.938Z","phase":"Phase 2","brief_title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT07078604","lead_sponsor":"University of Washington","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-07-22"},{"id":"95dd2ce0-ed59-4a61-b9b8-24f3c51885f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020065","created_at":"2025-06-14T13:53:41.046Z","updated_at":"2025-06-14T13:53:41.046Z","phase":"Phase 2","brief_title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 \u003c50%","source_id_and_acronym":"NCT07020065","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-13"},{"id":"cab8053f-6a2a-419a-97ce-e6c8bbd0a512","acronym":"NeoCARD","url":"https://clinicaltrials.gov/study/NCT06845319","created_at":"2025-02-27T07:07:22.165Z","updated_at":"2025-02-27T07:07:22.165Z","phase":"Phase 2","brief_title":"Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT06845319 - NeoCARD","lead_sponsor":"Medical University of South Carolina","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-25"},{"id":"089a9873-0dbf-4d04-a926-ae092495901f","acronym":"ComboMATCH","url":"https://clinicaltrials.gov/study/NCT05554380","created_at":"2022-09-26T14:56:10.419Z","updated_at":"2025-02-25T12:38:22.753Z","phase":"Phase 2","brief_title":"Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554380 - ComboMATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT2","pipe":" | ","alterations":" AKT1 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-24"},{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"0d632197-009b-4cc8-8b15-f154cec2fe79","acronym":"ACCIO","url":"https://clinicaltrials.gov/study/NCT04267848","created_at":"2021-01-18T20:44:14.334Z","updated_at":"2025-02-25T12:37:33.994Z","phase":"Phase 3","brief_title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial","source_id_and_acronym":"NCT04267848 - ACCIO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 1210","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-24"},{"id":"65fa5200-d596-487d-929e-1fa05dc863a1","acronym":"NRG-GY007","url":"https://clinicaltrials.gov/study/NCT02713386","created_at":"2021-01-18T13:15:58.271Z","updated_at":"2025-02-25T12:26:27.453Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02713386 - NRG-GY007","lead_sponsor":"NRG Oncology","biomarkers":" BRCA1 • BRCA2 • BRCA • CRP","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"9931d5cb-ec1d-4d84-a61e-6fecdc2e8707","acronym":"ACCESS-I","url":"https://clinicaltrials.gov/study/NCT06670911","created_at":"2025-02-25T12:31:12.020Z","updated_at":"2025-02-25T12:31:12.020Z","phase":"Phase 2","brief_title":"Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.","source_id_and_acronym":"NCT06670911 - ACCESS-I","lead_sponsor":"Instituto Nacional de Cancer, Brazil","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/20/2025","start_date":" 02/20/2025","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"488850a4-401a-418b-88e8-32f7b6c5f0dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038578","created_at":"2023-09-15T18:09:55.230Z","updated_at":"2025-02-25T13:41:43.311Z","phase":"Phase 2","brief_title":"A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer","source_id_and_acronym":"NCT06038578","lead_sponsor":"Toray Industries, Inc","biomarkers":" CAPRIN1","pipe":"","alterations":" ","tags":["CAPRIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • TRK-950"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-21"},{"id":"f40744c7-793a-45a6-9a12-58302eebd647","acronym":"ECOG-ACRIN 5103","url":"https://clinicaltrials.gov/study/NCT00433511","created_at":"2021-01-18T01:31:45.738Z","updated_at":"2025-02-25T13:47:58.144Z","phase":"Phase 3","brief_title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","source_id_and_acronym":"NCT00433511 - ECOG-ACRIN 5103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4994","initiation":"Initiation: 11/02/2007","start_date":" 11/02/2007","primary_txt":" Primary completion: 01/07/2014","primary_completion_date":" 01/07/2014","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2025-02-20"},{"id":"8edf0eb7-d0e0-49b2-b787-cd7e18808b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT02597946","created_at":"2021-01-18T12:36:41.049Z","updated_at":"2025-02-25T14:00:49.865Z","phase":"Phase 2","brief_title":"Afatinib in NSCLC With HER2 Mutation","source_id_and_acronym":"NCT02597946","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • KIT","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2 • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 07/22/2018","primary_completion_date":" 07/22/2018","study_txt":" Completion: 07/22/2018","study_completion_date":" 07/22/2018","last_update_posted":"2025-02-19"},{"id":"94997e45-2dee-4e97-9985-6f9da960c39e","acronym":"BROCADE3","url":"https://clinicaltrials.gov/study/NCT02163694","created_at":"2021-01-17T17:32:00.170Z","updated_at":"2025-02-25T14:06:48.816Z","phase":"Phase 3","brief_title":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer","source_id_and_acronym":"NCT02163694 - BROCADE3","lead_sponsor":"AbbVie","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 513","initiation":"Initiation: 04/08/2014","start_date":" 04/08/2014","primary_txt":" Primary completion: 04/05/2019","primary_completion_date":" 04/05/2019","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2025-02-19"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"734fb6ec-a3fe-4fc6-b873-fdb6107121be","acronym":"KEYNOTE-B21","url":"https://clinicaltrials.gov/study/NCT04634877","created_at":"2021-01-19T20:37:16.755Z","updated_at":"2025-02-25T14:08:01.972Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","source_id_and_acronym":"NCT04634877 - KEYNOTE-B21","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • docetaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 990","initiation":"Initiation: 01/10/2021","start_date":" 01/10/2021","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-17"}]